ACUTA CAPITAL PARTNERS, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001582844

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 34 positions · Total reported value $126.75M · Top-10 concentration 70.0% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 52.9% · 11 new · 7 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -16.4% · vs SPY -18.5% · Prev Value $143.49M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -8.3% · vs SPY -10.5% · Latest Value $126.75M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, ACUTA CAPITAL PARTNERS, LLC disclosed 34 equity positions with a combined reported value of $126.75M. The filing implies a focused portfolio: its ten largest positions account for 70.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PRAX ($24.52M), WHWK ($17.62M), TNGX ($10.22M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, ACUTA CAPITAL PARTNERS, LLC opened 11 new positions, trimmed 7 and fully exited 0, a turnover rate of 52.9% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q3 2026 were SLN ($4.30M), IRD ($2.49M), ACAD ($2.02M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SLN SILENCE THERAPEUTICS PLC · $4.30M
  • IRD OPUS GENETICS INC · $2.49M
  • ACAD ACADIA PHARMACEUTICALS INC · $2.02M
  • RVMD REVOLUTION MEDICINES INC · $1.69M
  • QNCX QUINCE THERAPEUTICS INC · $1.64M
  • ROIV ROIVANT SCIENCES LTD · $1.52M
  • ORIC ORIC PHARMACEUTICALS INC · $1.18M
  • ANTX AN2 THERAPEUTICS INC · $755.71K

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest ACUTA CAPITAL PARTNERS, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Acuta Capital Partners, based in Redwood City, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 34 positions worth $126.75M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: REDWOOD CITY, CA, United States
  • SEC registration: 801-136966 (status: Approved), registered 2026-09-09
  • Regulatory AUM (Form ADV): $172.53M as of 2026-06-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds
  • Website: acutacapital.com

Portfolio Structure

  • 34 positions · $126.75M reported value (Q3 2026)
  • Top 10 holdings = 70.0% of reported value
  • Largest position: PRAX (PRAXIS PRECISION MEDICINES I) at 19.3%
  • Average position size: $3.73M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 11 new, 10 added, 7 reduced
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to biotech/healthcare names (11 new positions, 34 total), with a bullish bias on clinical-stage therapeutics (e.g., PRAX, TNGX, ARGX) but selectively reducing overvalued or underperforming positions (AVBP, SRZN). 2. Key moves: - Added: PRAX (+1.7% shares), TNGX (+4.8%), FDMT (+5.4%), ARGX (+18.1%), OCUL (+7.9%), and new holding SLN. - Reduced: AVBP (-21.9% shares), SRZN (-12.0%). - Held: WHWK, DRUG. 3. Portfolio structure: Highly active, concentrated in Health Care (100% of top 10), with high risk appetite (small-cap biotech, clinical-stage pipelines). 4. Per-holding one-liner: - PRAX: Praxis Precision Medicines (cancer genomics). - WHWK: Whitehawk Therapeutics (RNA-targeted therapeutics). - TNGX: Tango Therapeutics (cancer genomics). - FDMT: 4D Molecular Therapeutics (gene therapy). - ARGX: Argenx (immune-oncology). - AVBP: Arrivent Biopharma (CNS disorders). - SRZN: Surrozen (Wnt pathway therapeutics). - DRUG: Bright Minds Biosciences (psychedelic therapeutics). - OCUL: Ocular Therapeutix (eye disease treatments). - SLN: Silence Therapeutics (RNA interference). 5. Style summary: Aggressive biotech investor doubling down on clinical-stage winners while trimming laggards.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 06:03

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 84.19K $24.52M 19.34%
19.34%
Add
2 4.69M $17.62M 13.90%
13.90%
Hold
3 409.53K $10.22M 8.06%
8.06%
Add
4 535.11K $7.66M 6.04%
6.04%
Add
5 5.56K $5.33M 4.21%
4.21%
Add
6 170.89K $5.17M 4.08%
4.08%
Reduce
7 152.54K $4.91M 3.87%
3.87%
Reduce
8 93.15K $4.64M 3.66%
3.66%
Hold
9 574.54K $4.41M 3.48%
3.48%
Add
10 393.58K $4.30M 3.39%
3.39%
New
11 691.84K $3.37M 2.66%
2.66%
Add
12 114.75K $3.27M 2.58%
2.58%
Hold
13 186.31K $2.86M 2.25%
2.25%
Hold
14 216.57K $2.53M 2.00%
2.00%
Hold
15 514.11K $2.49M 1.96%
1.96%
New
16 729.50K $2.44M 1.93%
1.93%
Add
17 52.72K $2.02M 1.60%
1.60%
Add
18 1.00K $2.02M 1.59%
1.59%
New
19 260.42K $1.85M 1.46%
1.46%
Hold
20 62.96K $1.83M 1.45%
1.45%
Reduce
21 8.24K $1.69M 1.33%
1.33%
New
22 52.92K $1.64M 1.29%
1.29%
New
23 41.53K $1.52M 1.20%
1.20%
New
24 115.39K $1.45M 1.14%
1.14%
Reduce
25 2.24K $1.21M 0.96%
0.96%
Add
26 89.83K $1.21M 0.95%
0.95%
Add
27 87.92K $1.18M 0.93%
0.93%
New
28 67.54K $990.15K 0.78%
0.78%
Reduce
29 142.05K $755.71K 0.60%
0.60%
New
30 129.98K $521.23K 0.41%
0.41%
New
31 25.29K $407.42K 0.32%
0.32%
Reduce
32 183.00K $297.38K 0.23%
0.23%
New
33 251.00K $261.04K 0.21%
0.21%
Reduce
34 5.77K $150.05K 0.12%
0.12%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 30% of its Top-10 each quarter and backtests at F1 70% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 70% · recall 70% · F1 70% · avg rank error 3.1 · Top-10 turnover 30%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 40% 40% 40% RYZB · CBAY · RCKT · EYPT · KURA · SRPT · PCVX · VRDN · IRON · MRSN OCUL · PRAX · MRSN · TSHA · RCKT · SRPT · PCVX · ELVN · TRML · APLT
2024-Q2 60% 60% 60% OCUL · MRSN · TSHA · SRPT · RCKT · PRAX · ELVN · PCVX · TRML · APLT OCUL · ELVN · PCVX · DYN · PRAX · CRNX · RCKT · TSHA · RVMD · INSM
2024-Q3 70% 70% 70% OCUL · ELVN · PCVX · DYN · CRNX · PRAX · INSM · RCKT · RVMD · TSHA PCVX · OCUL · TRML · INSM · ELVN · CRNX · ACLX · MREO · RVMD · TSHA
2024-Q4 70% 70% 70% PCVX · OCUL · TRML · INSM · ELVN · CRNX · MREO · ACLX · RVMD · KURA OCUL · INSM · TRML · CRNX · ELVN · WHWK · PRAX · RVMD · ARGX · PCVX
2025-Q1 70% 70% 70% OCUL · INSM · TRML · CRNX · WHWK · ELVN · PRAX · RVMD · ARGX · TRVI OCUL · INSM · TRML · WHWK · TRVI · SLNO · ARGX · ASND · PRAX · CDTX
2025-Q2 90% 90% 90% OCUL · INSM · TRML · WHWK · TRVI · SLNO · ARGX · ASND · PRAX · CDTX OCUL · CDTX · WHWK · SLNO · TRML · ASND · INSM · ARGX · PRAX · JAZZ
2025-Q3 70% 70% 70% CDTX · OCUL · WHWK · SLNO · TRML · ASND · ARGX · INSM · PRAX · JAZZ OCUL · CDTX · TRML · WHWK · INSM · DRUG · ARGX · AMLX · TERN · JAZZ
2025-Q4 80% 80% 80% CDTX · OCUL · TRML · WHWK · DRUG · INSM · ARGX · AMLX · TERN · JAZZ TERN · PRAX · CDTX · OCUL · WHWK · DRUG · CMPX · JAZZ · INSM · ARGX
2026-Q1 70% 70% 70% TERN · PRAX · CDTX · OCUL · WHWK · DRUG · CMPX · JAZZ · INSM · SRZN PRAX · TERN · WHWK · TNGX · DRUG · STRO · ERAS · SRZN · OCUL · CMPX
2026-Q2 80% 80% 80% PRAX · TERN · WHWK · TNGX · DRUG · STRO · ERAS · SRZN · OCUL · CMPX PRAX · WHWK · TNGX · STRO · AVBP · FDMT · DRUG · OCUL · ERAS · SRZN
2026-Q3 ★ 70% 70% 70% PRAX · WHWK · TNGX · STRO · AVBP · FDMT · DRUG · OCUL · MLTX · ERAS PRAX · WHWK · TNGX · FDMT · ARGX · AVBP · SRZN · DRUG · OCUL · SLN

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings8 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-15.40%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+1.62%vs benchmark
Barra annualised vol49.8%Model estimate
Realised vol63.0%Annualised in window
Weighted beta1.10Raw exposure
Factor / specific risk40% / 60%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)77.984.791.598.3105.010-0110-2311-16ACUTA CAPITAL PARTNERS, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-15.40%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+1.62%Portfolio − benchmark
Arithmetic return sum-14.10%Difference vs compounded is the cross term
Weighted raw beta1.10Weighted holding betas
Realised volatility (annualised)63.01%Daily returns in window
Barra model volatility (annualised)49.79%Factor + specific
Factor share of variance40.4%Barra factors
Specific share of variance59.6%Stock residuals
Reported value$29.7M13F long US equity

2. Return attribution

The -14.10% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -1.71% -12.1%
Momentum & Growth 3 -8.19% -58.1%
Volatility & Tail Risk 7 -4.43% -31.4%
Industry 12 +6.98% 49.5%
Specific 1 -6.75% -47.9%
Return attribution (style + industry, %)-12.5-6.3+0.0+6.3+12.5Amihud Illiquidity-0.92Max Drawdown-0.93Beta+1.10Growth-1.17Non-linear Size+2.27Turnover-2.67Size+2.76Skewness-2.92Mid Cap-3.26Kurtosis+4.80Residual Volatility+5.74Health Care+6.98Momentum-7.06Historical Volatility-11.60
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +6.98% +6.98% 49.5%
Residual Volatility Style +1.74 +3.29% +5.74% 40.7%
Kurtosis Style +0.64 +7.51% +4.80% 34.0%
Size Style -1.42 -1.95% +2.76% 19.6%
Non-linear Size Style +2.25 +1.01% +2.27% 16.1%
Beta Style +0.25 +4.44% +1.10% 7.8%
Liquidity Style +0.31 +0.36% +0.11% 0.8%
Leverage (Downside Vol) Style +0.37 -1.71% -0.63% -4.5%
Amihud Illiquidity Style +2.07 -0.45% -0.92% -6.5%
Max Drawdown Style +0.53 -1.76% -0.93% -6.6%
Growth Style -0.67 +1.75% -1.17% -8.3%
Turnover Style +0.56 -4.80% -2.67% -18.9%
Skewness Style +0.67 -4.39% -2.92% -20.7%
Mid Cap Style +1.68 -1.94% -3.26% -23.1%
Specific Specific — — -6.75% -47.9%
Momentum Style +1.76 -4.00% -7.06% -50.0%
Historical Volatility Style +0.83 -14.00% -11.60% -82.2%

3. Risk attribution

Annualised volatility is 49.79%; factor risk explains 40.4% of variance and specific risk 59.6%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-64.4-32.2+0.0+32.2+64.4Turnover+0.36Max Drawdown+0.53Leverage (Downside Vol)+1.03Beta+1.17Skewness+1.36Non-linear Size+1.39Amihud Illiquidity+1.73Residual Volatility+3.41Historical Volatility+3.67Size+3.94Mid Cap+4.35Momentum+6.71Health Care+10.68Specific+59.61
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 59.6% +29.68% 29.7%
Health Care Industry +1.00 10.7% +5.32% 5.3%
Momentum Style +1.76 6.7% +3.34% 3.3%
Mid Cap Style +1.68 4.3% +2.17% 2.2%
Size Style -1.42 3.9% +1.96% 2.0%
Historical Volatility Style +0.83 3.7% +1.83% 1.8%
Residual Volatility Style +1.74 3.4% +1.70% 1.7%
Amihud Illiquidity Style +2.07 1.7% +0.86% 0.9%
Non-linear Size Style +2.25 1.4% +0.69% 0.7%
Skewness Style +0.67 1.4% +0.68% 0.7%
Beta Style +0.25 1.2% +0.58% 0.6%
Leverage (Downside Vol) Style +0.37 1.0% +0.51% 0.5%
Max Drawdown Style +0.53 0.5% +0.26% 0.3%
Turnover Style +0.56 0.4% +0.18% 0.2%
Growth Style -0.67 0.2% +0.10% 0.1%
Kurtosis Style +0.64 -0.2% -0.11% -0.1%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.8-0.70.41.52.6Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.42 +2.10 -3.52
Non-linear Size +2.25 +1.68 +0.58
Mid Cap +1.68 +0.13 +1.56
Beta +0.25 +1.29 -1.05
Momentum +1.76 +0.72 +1.05
Short-term Reversal +0.04 -0.64 +0.68
Residual Volatility +1.75 -0.40 +2.15
Historical Volatility +0.83 +0.86 -0.03
Liquidity +0.31 +0.11 +0.20
Amihud Illiquidity +2.07 +1.16 +0.91
Turnover +0.56 +0.21 +0.35
Growth -0.67 +0.58 -1.25
Leverage (Downside Vol) +0.37 +0.14 +0.22
Skewness +0.67 +0.24 +0.43
Kurtosis +0.64 +0.21 +0.42
Max Drawdown +0.53 -0.08 +0.61

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -15.44% +8.29% +24.98% -0.41% -23.31% -15.58%
Total +23.98% +15.43% -39.16% +0.26%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
TNGX TANGO THERAPEUTICS INC Health Care 34.38% -3.13% -1.07% Add
ARGX ARGENX SE Health Care 17.93% -0.83% -0.15% Add
AVBP ARRIVENT BIOPHARMA INC Health Care 17.41% -61.82% -10.76% Reduce
TSHA TAYSHA GENE THERAPIES INC Health Care 11.34% -16.63% -1.89% Add
RVMD REVOLUTION MEDICINES INC Health Care 5.69% -18.70% -1.06% New
ROIV ROIVANT SCIENCES LTD Health Care 5.11% +5.58% +0.29% New
UTHR UNITED THERAPEUTICS CORP DEL Health Care 4.08% +8.49% +0.35% Add
CTNM CONTINEUM THERAPEUTICS INC Health Care 4.06% -27.94% -1.13% Add
Contribution rank Symbol Sector Weight Return Contribution
1 UTHR Health Care 4.08% +8.49% +0.35%
2 ROIV Health Care 5.11% +5.58% +0.29%
3 ARGX Health Care 17.93% -0.83% -0.15%
4 RVMD Health Care 5.69% -18.70% -1.06%
5 TNGX Health Care 34.38% -3.13% -1.07%
6 CTNM Health Care 4.06% -27.94% -1.13%
7 TSHA Health Care 11.34% -16.63% -1.89%
8 AVBP Health Care 17.41% -61.82% -10.76%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -15.40%, versus -17.01% for the QQQ synthetic benchmark — an excess of +1.62%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +6.98%, Residual Volatility +5.74%, Kurtosis +4.80%; the largest drags came from Historical Volatility -11.60%, Momentum -7.06%, Mid Cap -3.26%. Specific (stock-level) return contributed -6.75%.
  3. Risk attribution: Barra model volatility is 49.79% annualised; factor risk explains 40% of variance and specific risk 60%. The largest factor risk sources are Health Care 10.7%, Momentum 6.7%, Mid Cap 4.3%.
  4. Style tilt: size -1.42, momentum +1.76, volatility +0.83, liquidity +0.31; the weighted raw beta is 1.10. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.43% and interaction -39.16%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did ACUTA CAPITAL PARTNERS, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, ACUTA CAPITAL PARTNERS, LLC reported 34 equity positions worth $126.75M in aggregate; its largest disclosed positions were PRAX ($24.52M), WHWK ($17.62M), TNGX ($10.22M).

How large is ACUTA CAPITAL PARTNERS, LLC's portfolio?

ACUTA CAPITAL PARTNERS, LLC reported $126.75M of long equity holdings across 34 positions as of 2026-Q3. Top-10 holdings account for 70.0% of reported value.

What is ACUTA CAPITAL PARTNERS, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/acuta-capital-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →